DK0595935T3 - Papillomavirusvaccine - Google Patents

Papillomavirusvaccine

Info

Publication number
DK0595935T3
DK0595935T3 DK92915973T DK92915973T DK0595935T3 DK 0595935 T3 DK0595935 T3 DK 0595935T3 DK 92915973 T DK92915973 T DK 92915973T DK 92915973 T DK92915973 T DK 92915973T DK 0595935 T3 DK0595935 T3 DK 0595935T3
Authority
DK
Denmark
Prior art keywords
protein
contg
proteins
vlps
derived
Prior art date
Application number
DK92915973T
Other languages
Danish (da)
English (en)
Inventor
Ian Frazer
Jian Zhou
Original Assignee
Csl Ltd
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3775561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0595935(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Ltd, Univ Queensland filed Critical Csl Ltd
Application granted granted Critical
Publication of DK0595935T3 publication Critical patent/DK0595935T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK92915973T 1991-07-19 1992-07-20 Papillomavirusvaccine DK0595935T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPK732291 1991-07-19
PCT/AU1992/000364 WO1993002184A1 (en) 1991-07-19 1992-07-20 Papilloma virus vaccine

Publications (1)

Publication Number Publication Date
DK0595935T3 true DK0595935T3 (da) 2003-07-21

Family

ID=3775561

Family Applications (3)

Application Number Title Priority Date Filing Date
DK02009841T DK1298211T3 (da) 1991-07-19 1992-07-20 Polynukleotidsegment af HPV16-genom
DK03005929T DK1359156T3 (da) 1991-07-19 1992-07-20 Vaccine mod humanpapillomavirus
DK92915973T DK0595935T3 (da) 1991-07-19 1992-07-20 Papillomavirusvaccine

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK02009841T DK1298211T3 (da) 1991-07-19 1992-07-20 Polynukleotidsegment af HPV16-genom
DK03005929T DK1359156T3 (da) 1991-07-19 1992-07-20 Vaccine mod humanpapillomavirus

Country Status (17)

Country Link
US (5) US7476389B1 (el)
EP (5) EP0595935B1 (el)
JP (3) JP3828570B2 (el)
KR (1) KR100240480B1 (el)
AT (3) ATE332973T1 (el)
AU (1) AU651727B2 (el)
CA (1) CA2113712C (el)
CY (5) CY2598B2 (el)
DE (11) DE122007000086I1 (el)
DK (3) DK1298211T3 (el)
ES (3) ES2267890T3 (el)
GE (1) GEP20084431B (el)
HK (1) HK1059271A1 (el)
LU (8) LU91315I2 (el)
NL (8) NL300261I1 (el)
SG (1) SG48769A1 (el)
WO (1) WO1993002184A1 (el)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE332973T1 (de) 1991-07-19 2006-08-15 Univ Queensland Polynukleotidabschnitt des hpv16-genoms
DE122007000098I1 (de) * 1992-06-25 2008-03-27 Papillomavirus vakzine
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
ATE296111T1 (de) * 1993-03-09 2005-06-15 Univ Rochester Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
AU719837B2 (en) * 1993-03-31 2000-05-18 Cancer Research Campaign Technology Limited Pharmaceuticals based on papillomaviruses
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
GB9313556D0 (en) * 1993-07-01 1993-08-18 British Tech Group Synthetic peptides of human papillomavirus
GB2279651A (en) * 1993-07-01 1995-01-11 British Tech Group Synthetic peptides of human papillomavirus
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
DE4415743C2 (de) * 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
SK147696A3 (en) * 1994-05-16 1997-08-06 Merck & Co Inc Isolated and purified protein of papillomavirus, a capside, a viral particle, pharmaceutical composition comprising its, a method of making them and their use
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
AU717932B2 (en) * 1994-10-06 2000-04-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
AU717647B2 (en) * 1994-10-06 2000-03-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
DE4447664C2 (de) * 1994-10-07 1999-04-15 Lutz Prof Dr Gissmann Fusionsproteine, Verfahren zu deren Herstellung sowie deren Anwendung
US6066324A (en) 1994-10-07 2000-05-23 Loyola University Of Chicago Carboxyl terminal of papilloma virus L1 region is not required for formation of virus-like particles
AU2003235191B2 (en) * 1994-10-07 2006-09-21 Loyola University Of Chicago Papilloma virus-like particles, fusion proteins as well as processes for their production
DE19526752C2 (de) * 1995-07-21 1997-08-07 Lutz Prof Dr Gissmann Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
EP0812358A1 (en) * 1995-02-24 1997-12-17 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
SE9501512D0 (sv) * 1995-04-24 1995-04-24 Euro Diagnostica Ab Synthetic peptide-defined eptopes useful for vaccination against papillomavirus
CA2237224C (en) * 1995-11-15 2006-06-27 Steven Ludmerer Synthetic hpv11 virus-like particles
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
CA2267639C (en) * 1996-10-04 2005-11-22 Merck & Co., Inc. Synthetic hpv16 virus-like particles
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
CA2274474C (en) * 1996-12-09 2008-07-22 Steven Ludmerer Synthetic hpv16 virus-like particles
AU5608798A (en) * 1996-12-20 1998-07-17 Merck & Co., Inc. Formulations of recombinant papillomavirus vaccines
AU750702B2 (en) * 1997-05-01 2002-07-25 Chiron Corporation Use of virus-like particles as adjuvants
WO1999001557A1 (en) * 1997-07-03 1999-01-14 University Of Colorado, University Technology Corporation Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
DE19925235A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925234A1 (de) * 1999-06-01 2000-12-14 Medigene Ag Capsomere, stabile Capsomere, Capside, VLPs, oder CVLPs bzw. damit beladenen Zellen und ihre Verwendung in Diagnostik und Therapie
DE19925199A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
KR100785397B1 (ko) 2001-06-28 2007-12-13 아피메즈 주식회사 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
DE60236806D1 (de) 2001-08-13 2010-08-05 Univ Rochester Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
US20050118139A1 (en) * 2001-08-23 2005-06-02 Lingyi Huang Vaccine using papilloma virus e proteins delivered by viral vector
KR20030067873A (ko) * 2002-02-08 2003-08-19 주식회사 유니크 솔레노이드 밸브
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7534585B2 (en) 2003-07-21 2009-05-19 Transgene S.A. Multifunctional cytokines
EP1664348B8 (en) * 2003-09-25 2019-06-12 Third Wave Technologies, Inc. Detection of hpv
ATE474596T1 (de) * 2004-09-10 2010-08-15 Asahi Glass Co Ltd Impfstoff gegen humanes papillomavirus zur oralen verabreichung
US8021992B2 (en) * 2005-09-01 2011-09-20 Taiwan Semiconductor Manufacturing Co., Ltd. High aspect ratio gap fill application using high density plasma chemical vapor deposition
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8080643B2 (en) * 2006-09-05 2011-12-20 Third Wave Technologies, Inc. HPV primers
HUE037808T2 (hu) 2006-09-26 2018-09-28 Infectious Disease Res Inst Szintetikus adalékanyagot tartalmazó vakcina kompozíció
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
AU2008223951B2 (en) 2007-03-02 2014-03-27 Glaxosmithkline Biologicals S.A. Novel method and compositions
RU2494106C2 (ru) * 2007-11-23 2013-09-27 Шанхай Зеран Биотекнолоджи Ко., Лтд. Гены, кодирующие главный капсидный белок l1 вируса папилломы человека, и их применение
KR101164602B1 (ko) 2008-01-09 2012-07-10 주식회사 케이알바이오텍 배큘로바이러스?기반 백신
ES2565846T3 (es) 2008-05-26 2016-04-07 Cadila Healthcare Limited Vacuna combinada contra el sarampión-papiloma humano
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
EP2414512A1 (en) * 2009-04-03 2012-02-08 Deutsches Krebsforschungszentrum Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
BRPI1011072B1 (pt) 2009-06-05 2021-09-28 Infectious Disease Research Institute Composto de gla, composições de vacina e farmacêutica compreendendo dito composto, bem como uso dos mesmos para estimular, induzir ou acentuar uma resposta imune em um indivíduo
KR101181907B1 (ko) 2009-06-19 2012-09-11 아이진 주식회사 자궁경부암 백신
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
WO2011127360A1 (en) 2010-04-08 2011-10-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
WO2011149897A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
KR101349291B1 (ko) 2010-08-10 2014-01-10 한국생명공학연구원 고초균을 이용하여 자궁경부암 백신을 제조하는 방법
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
RS58868B1 (sr) 2012-02-07 2019-08-30 Infectious Disease Res Inst Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
EP2827891A1 (en) 2012-03-18 2015-01-28 GlaxoSmithKline Biologicals S.A. Method of vaccination against human papillomavirus
KR102136433B1 (ko) 2012-05-16 2020-07-22 이뮨 디자인 코포레이션 Hsv-2 백신
CN104870477B (zh) 2012-10-23 2018-10-09 爱默蕾大学 Gm-csf和il-4轭合物、组合物以及与其相关的方法
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
JP6741580B2 (ja) 2013-12-31 2020-08-19 インフェクシャス ディズィーズ リサーチ インスティチュート 単一バイアルのワクチン製剤
WO2016149384A1 (en) * 2015-03-18 2016-09-22 University Of Massachusetts Virus-like particle compositions and vaccines against epstein-barr virus infection and disease
KR101908438B1 (ko) * 2016-02-05 2018-10-16 (주)피앤피바이오팜 Arsntd를 융합파트너로 이용한 수용성 및 활성형 재조합단백질의 생산방법 및 그 생산물
EP3420355A1 (en) 2016-02-22 2019-01-02 Boehringer Ingelheim Vetmedica GmbH Method for the immobilization of biomolecules
KR102483033B1 (ko) 2016-05-16 2022-12-30 액세스 투 어드밴스드 헬스 인스티튜트 페길화된 리포솜 및 이의 용도
US11344619B2 (en) 2016-05-16 2022-05-31 Access To Advanced Health Institute Formulation containing TLR agonist and methods of use
MX2021010105A (es) 2016-06-01 2022-06-16 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento.
KR20200028395A (ko) 2017-06-15 2020-03-16 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
JP7339942B2 (ja) 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート サポニンを含むリポソーム製剤および使用方法
RU2681174C1 (ru) * 2018-07-12 2019-03-04 Закрытое акционерное общество научно-производственная компания "Комбиотех" Способ получения рекомбинантной вакцины для профилактики папилломавирусной инфекции человека, рекомбинантная вакцина
CN114340665A (zh) 2019-05-25 2022-04-12 传染病研究所 用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
JP7017811B2 (ja) * 2020-02-13 2022-02-09 国立研究開発法人農業・食品産業技術総合研究機構 ウイルス様粒子及びその使用
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
CN117222428A (zh) 2021-02-11 2023-12-12 葛兰素史克生物有限公司 Hpv疫苗生产
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2524487B1 (fr) 1982-04-05 1985-11-22 Pasteur Institut Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants
US5071757A (en) 1986-10-06 1991-12-10 Kreider John W Methods for propagating fastidious human viruses and for producing purified suspensions thereof
US5045447A (en) 1989-03-15 1991-09-03 Minson Anthony C Method of producing antibodies to HPV
NL8902301A (nl) * 1989-09-14 1991-04-02 Rijksuniversiteit Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins.
WO1992016638A1 (en) * 1991-03-14 1992-10-01 5 Prime --> 3 Prime, Inc. Transduction vehicles for transferring dna to a mammalian cell
ATE332973T1 (de) 1991-07-19 2006-08-15 Univ Queensland Polynukleotidabschnitt des hpv16-genoms
DE122007000098I1 (de) 1992-06-25 2008-03-27 Papillomavirus vakzine
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
ATE296111T1 (de) 1993-03-09 2005-06-15 Univ Rochester Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen

Also Published As

Publication number Publication date
DE122007000086I1 (de) 2008-04-17
HK1059271A1 (en) 2004-06-25
LU91316I2 (fr) 2007-04-27
EP1207203A3 (en) 2004-04-28
EP0595935A1 (en) 1994-05-11
CY2007015I1 (el) 2009-11-04
DE69233687D1 (de) 2007-04-19
NL300261I1 (nl) 2007-05-01
EP1298211A3 (en) 2003-04-16
ES2194839T3 (es) 2003-12-01
CY2598B2 (en) 2010-03-03
CY2007030I1 (el) 2012-01-25
AU651727B2 (en) 1994-07-28
DE69232967D1 (de) 2003-04-24
US7169585B2 (en) 2007-01-30
EP1359156A2 (en) 2003-11-05
US7939082B2 (en) 2011-05-10
DE69233639T2 (de) 2007-05-31
EP1471147A3 (en) 2007-03-21
CY2007015I2 (el) 2016-08-31
EP1298211A2 (en) 2003-04-02
EP0595935A4 (en) 1995-03-29
LU91385I2 (fr) 2008-02-14
JP4255944B2 (ja) 2009-04-22
DK1359156T3 (da) 2007-04-10
DE69233639D1 (de) 2006-08-24
NL300262I1 (nl) 2007-05-01
DK1298211T3 (da) 2006-11-13
EP1207203A2 (en) 2002-05-22
AU2366692A (en) 1993-02-23
LU91321I2 (fr) 2007-05-09
ES2267890T3 (es) 2007-03-16
DE122007000018I1 (de) 2007-05-24
US20070154902A1 (en) 2007-07-05
GEP20084431B (en) 2008-07-25
US20040214331A1 (en) 2004-10-28
DE69232967T2 (de) 2003-12-18
LU91387I2 (fr) 2008-02-14
JP2004000269A (ja) 2004-01-08
JP3828570B2 (ja) 2006-10-04
ES2279020T3 (es) 2007-08-16
CA2113712A1 (en) 1993-02-04
DE122007000085I1 (de) 2008-03-27
ATE356142T1 (de) 2007-03-15
KR100240480B1 (ko) 2000-03-02
NL300263I1 (nl) 2007-05-01
EP1359156A3 (en) 2004-03-24
EP1359156B1 (en) 2007-03-07
NL300314I2 (nl) 2010-03-01
DE122007000023I1 (de) 2007-08-09
DE69233687T2 (de) 2007-10-18
LU91315I2 (fr) 2007-04-27
ATE332973T1 (de) 2006-08-15
JP2006115849A (ja) 2006-05-11
LU91317I2 (fr) 2007-04-27
ATE234925T1 (de) 2003-04-15
LU91386I2 (fr) 2008-02-14
CY2007016I2 (el) 2009-11-04
DE122007000084I1 (de) 2008-03-27
NL300314I1 (nl) 2008-02-01
DE122007000016I1 (de) 2007-05-24
NL300312I1 (nl) 2008-02-01
EP1471147A2 (en) 2004-10-27
WO1993002184A1 (en) 1993-02-04
CY2007030I2 (el) 2017-04-05
JPH07505042A (ja) 1995-06-08
DE122007000019I1 (de) 2007-07-26
CY2007034I1 (el) 2012-01-25
US7476389B1 (en) 2009-01-13
EP0595935B1 (en) 2003-03-19
US20090252761A1 (en) 2009-10-08
DE122007000017I1 (de) 2007-07-26
EP1298211B1 (en) 2006-07-12
LU91318I2 (fr) 2007-04-27
CY2007016I1 (el) 2009-11-04
NL300313I1 (nl) 2008-02-01
CA2113712C (en) 2007-06-12
US6613557B1 (en) 2003-09-02
NL300260I1 (nl) 2007-05-01
NL300266I1 (nl) 2007-05-01
SG48769A1 (en) 1998-05-18

Similar Documents

Publication Publication Date Title
DK0595935T3 (da) Papillomavirusvaccine
NL300323I1 (nl) Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze
DE122011100018I1 (de) Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen.
CA2339324A1 (en) Protein delivery system using human papillomavirus virus-like particles